Miller D R, Krailo M, Bleyer W A, Lukens J N, Siegel S E, Coccia P R, Weiner J, Hammond D
Cancer Treat Rep. 1985 Oct;69(10):1211-21.
The Childrens Cancer Study Group (CCSG) has evaluated French-American-British (FAB) morphology in newly diagnosed children with acute lymphoblastic leukemia (ALL) since 1975. A modification of the FAB system was used in which individual lymphoblast cells were scored and designated as either L1 or L2 on the basis of distinctive morphologic characteristics. L1 ALL was defined as less than 10% L2 cells and greater than 90% L1 cells; L2 ALL was defined as greater than or equal to 10% L2 cells and less than 90% L1 cells. FAB morphology was an independent predictor of overall survival (P = 0.02) in CCSG-141 and a highly significant predictor of successful induction of complete remission and event-free survival in the CCSG-160 series (P = 0.00001). These studies involved nearly 3900 patients. Two concordance studies have been performed. In the first (1981) study, overall concordance between the FAB reference laboratory and member institutions was 76% using a two-category system (L1, non-L1), 86% for L1 cases, and 47% for non-L1 cases. In the second (1984) concordance study, the use of more stringent, semiquantitative definitions of L1 and L2 lymphoblasts did not improve overall (75%), L1 (89%), or non-L1 (46%) concordance. The results of reference laboratory classification more powerfully predicted event-free survival than did member institutions (P = 0.016 vs P = 0.125). Quality control factors (slide preparation, cellularity, staining quality, and discipline of the reviewer) did not influence concordance. These results justify the continued assignment of patients to protocols of the CCSG-100 series on the basis of the modified FAB classification. The biological significance of the FAB morphologic variants remains to be determined.
自1975年以来,儿童癌症研究组(CCSG)对新诊断的急性淋巴细胞白血病(ALL)患儿进行了法国-美国-英国(FAB)形态学评估。采用了FAB系统的一种改良方法,根据独特的形态学特征对单个原始淋巴细胞进行评分,并将其指定为L1或L2。L1型ALL定义为L2细胞少于10%且L1细胞大于90%;L2型ALL定义为L2细胞大于或等于10%且L1细胞少于90%。FAB形态学是CCSG - 141中总生存的独立预测因素(P = 0.02),也是CCSG - 160系列中完全缓解成功诱导和无事件生存的高度显著预测因素(P = 0.00001)。这些研究涉及近3900名患者。进行了两项一致性研究。在第一项(1981年)研究中,使用两类系统(L1,非L1)时,FAB参考实验室与成员机构之间的总体一致性为76%,L1病例为86%,非L1病例为47%。在第二项(1984年)一致性研究中,对L1和L2原始淋巴细胞使用更严格的半定量定义并未提高总体(75%)、L1(89%)或非L1(46%)的一致性。参考实验室分类结果比成员机构更有力地预测了无事件生存(P = 0.016对P = 0.125)。质量控制因素(玻片制备、细胞密度、染色质量和审阅者的严谨性)不影响一致性。这些结果证明基于改良的FAB分类继续将患者分配到CCSG - 100系列方案是合理的。FAB形态学变异的生物学意义仍有待确定。